Drugs / Maalox
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01930045 | Oct → Dec 2013 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02245269 | Jul → Oct 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06819033 | Mar 2025 → Feb 2026 overdue | aphthous stomatitis | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT02300727 Comparator | Feb 2015 → Oct 2018 | mucositis | Amy Beres | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06241183 Comparator | Nov 2023 → Dec 2027 expected | dyspepsia, gastroesophageal reflux disease | Stony Brook University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAALOX | “The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine.” NCT02300727 ↗ |
| Known as | MAL | “MAALOX (MAL)” NCT01930045 ↗ |
| Route | Oral | “30 ml of oral Maalox/ Mylanta” NCT06241183 ↗ |